OR WAIT null SECS
January 18, 2021
The 40,000-ft.2 facility will feature eight cleanrooms with configurations for the production of cell and viral vector products.
January 15, 2021
The collaboration will focus on up to three types of lung and gastrointestinal cancers.
The acquisition significantly expands Precision Medicine Group’s cell and gene therapy expertise.
The fill line will work to manufacture high-value APIs for drug product manufacturing to meet the needs of the COVID-19 pandemic.
January 14, 2021
The 17,000 m2 facility will serve as a process development and manufacturing site for Chinese companies developing medicines as well as multinationals with manufacturing requirements in China.
The service uses Hovione’s Intelligent PROprietary Screening methodology to screen for combinations of polymers, drug loads, surfactants, and solvents with an advanced computational tool.
January 13, 2021
CMIC will work to advance decentralized trials in Japan.
Acorda’s Chelsea, MA facility will serve as a global center of excellence in the Catalent network for spray-dried dispersion and dry powder encapsulation and packaging.
January 12, 2021
Under the terms of the agreement, operations will be initiated at Lonza’s Houston, TX Center of Excellence where Lonza will handle process development activities for late-clinical and commercial-scale GMP manufacturing of the cell therapy.
January 11, 2021
A strategic separation is designed to enhance the value and growth of Paraxel’s contract research services and Calyx’s imaging businesses.